Univariate and multivariate analyses found that ECOG PS, brain metastasis, bone metastasis, surgical history, chemotherapy, and baseline anemia were independent prognostic factors for OS in patients with stage IV EGFR-mutated NSCLC who received targeted therapy. This evidence concerns the gene EGFR and bone metastasis.